On Friday, Shares of CEL-SCI Corporation (NYSEMKT:CVM), gained 16.21% to $1.04.
Cancer immunotherapy is scorching hot. At no time in medical history has a new cancer treatment been so widely researched and highly paid for. Over the last 50 years, the only medicine for cancer has been radiation and chemotherapy, and a few monoclonal antibodies with side effects not much better, barbaric contrast to this new wave of ways to combat the disease.
Leading this charge is CEL-SCI Corporation, far above competitors, in Phase III clinical trials with Multikine, a potent cocktail of immune system activators for head and neck cancer (and other infectious diseases). After a misstep with an incompetent contract research organization (CRO) to run studies, the company regrouped and hired two global oncology experts - Aptiv Solutions and Ergomed, the latter which, also serving multi-billion dollar Sanofi (SNY:NYSE), will contribute up to $10 million to the development of Multikine for its cancer indication in exchange for a very small royalty payment when the drug is approved and on the market. I credit the savvy of Cel-Sci’s CEO, Geert Kersten, long-time advocate of the technology, for inking this terrific deal.
CEL-SCI Corporation engages in the research and development of drugs and vaccines. The company’s lead investigational immunotherapy is Multikine, which is under pivotal phase III clinical trial for the treatment of primary head and neck cancer.
Shares of Agenus Inc. (NASDAQ:AGEN), surged 11.77% to $7.12, during its last trading session.
Agenus, declared that final results from a large-scale Phase 3 study of GlaxoSmithKline’s (GSK) malaria vaccine candidate, RTS,S, were published in The Lancet. The study demonstrated a statistically noteworthy reduction against malaria in children who received RTS,S followed by a booster shot of the vaccine at 18 months. RTS,S incorporates QS-21 Stimulon®, Agenus’ adjuvant designed to enhance the immune response to antigens in vaccines.
The study results also showed:
- RTS,S reduced the number of cases of clinical malaria in young children (aged 5-17 months at first vaccination) by 36%, and in infants (aged 6-12 weeks) by 26% over an average follow-up period of 48 months.
- This resulted in an average reduction of 1,774 cases of clinical malaria for every 1,000 children vaccinated (aged 5-17 months), and an average reduction of 983 cases of clinical malaria for every 1,000 infants vaccinated over an average 36-month follow-up. Children receiving the vaccine candidate but not a booster dose had lower rates of protection. The study showed that RTS,S averted even more cases of malaria in areas with higher transmission rates.
Agenus Inc., an immunotherapy company, engages in discovering and developing innovative treatments for patients with cancer and other diseases. Its treatments focus on providing therapeutic benefit through modulation of immune function.
At the end of Friday’s trade, Shares of Aaron’s, Inc. (NYSE:AAN), jumped 11.68% to $32.80.
Aaron’s, declared revenues and earnings for the three months ended March 31, 2015.
For the first quarter of 2015, revenues raised 40.4% to $821.8 million contrast with $585.4 million for the first quarter of 2014. Net earnings raised 28.4% to $49.2 million contrast with $38.3 million in the preceding year period. Diluted earnings per share were $.68 contrast with $.53 a year ago. Non-GAAP earnings per share were $.73 contrast with $.53 last year.
Financial Summary
On a non-GAAP basis, not taking into account the $6.6 million of amortization expense related to the acquisition of Progressive, net earnings for the first quarter of 2015 were $53.4 million contrast with $38.3 million in the first quarter a year ago, and diluted earnings per share were $.73 contrast with $.53.
EBITDA for the Company was $103.7 million for the first quarter of 2015 contrast with $76.3 million in the preceding year period. EBITDA is calculated as the Company’s earnings before interest, depreciation on property, plant and equipment, amortization of intangible assets and income taxes.
The Company ended the first quarter of 2015 with $129.8 million in cash contrast with $3.5 million at the end of 2014. Debt was reduced to $520.7 million at March 31, 2015 from $606.1 million at December 31, 2014.
Aaron’s, Inc. operates as a specialty retailer of furniture, consumer electronics, computers, appliances, and household accessories in the United States and Canada. The company operates in five segments: Sales and Lease Ownership, Progressive, HomeSmart, Franchise, and Manufacturing.
Finally, Acacia Research Corporation (NASDAQ:ACTG), ended its last trade with 10.78% gain, and closed at $11.10.
Acacia Research Corporation, stated results for the three months ended March 31, 2015.
- Revenues for the first quarter of 2015 were $34,210,000, as contrast to $12,578,000 in the comparable preceding year quarter.
- GAAP net loss for the first quarter of 2015 was $13,130,000, or $0.27 per diluted share, as contrast to $24,421,000, or $0.51 per diluted share for the comparable preceding year quarter.
- Non-GAAP net income for the first quarter of 2015 was $3,155,000, or $0.06 per diluted share, as contrast to a Non-GAAP net loss of $5,184,000, or $0.11 per diluted share for the comparable preceding year quarter. See below for information regarding non-GAAP measures.
- Cash and cash equivalents, restricted cash and investments totaled $165,555,000 as of March 31, 2015.
Acacia Research Corporation, through its auxiliaries, invests in, develops, licenses, and enforces patented technologies in the United States. It assists patent owners with the prosecution and development of their patent portfolios.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.